<DOC>
	<DOCNO>NCT02355353</DOCNO>
	<brief_summary>The primary objective study correlate percentage change apparent diffusion coefficient ( ADC ) baseline early therapy ( day 14 ) tumor regression grade ( TRG ) measure surgical resection specimen .</brief_summary>
	<brief_title>Evaluation Diffusion Weighted Imaging -MRI Patients With Resectable Liver Metastases From Colorectal Cancer</brief_title>
	<detailed_description>This prospective , multicenter , single-arm image trial . Patients resectable liver metastasis colorectal cancer ( CRC ) undergo Diffusion Weighted Imaging- Magnetic Resonance Imaging ( DWI-MRI ) scan least three separate occasion : baseline , 14 day ( maximum +/- 1 day deviation acceptable ) first administration chemotherapy finally 6 cycle chemotherapy ( one week prior surgery ) . All patient register study may participate test-retest analysis . This analysis require double baseline scan ( call test-retest ) do two separate occasion , separate one hour one week start therapy . The repeated scan baseline ( retest ) optional use test-retest repeatability analysis . Dedicated in-house developed software use quantify ADC assess tumor characteristic response therapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Histologically proven CRC metachronous synchronous liver metastasis consider completely upfront resectable . Patients least one measurable liver lesion ( &gt; 2 cm ) , measure contrast CT MRI baseline . At least one liver metastasis clearly identify provide high likelihood successful resection later surgery . Patients must 18 year old old . A World Health Organization ( WHO ) performance status 0 1 . Previous adjuvant chemotherapy primary CRC allow complete least 12 month inclusion study . All following test do within 6 week prior registration : Hematological status : neutrophil ( ANC ) ≥ 1.5x109/L ; platelet ≥ 100x109/L ; haemoglobin ≥ 9g/dL . Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) . No significant proteinuria ( &lt; 2+ proteinuria urine dipstick urine protein &lt; 1g/24 hour urine collection ) . Liver function : serum bilirubin ≤ 1.5 x ULN , alkaline phosphatase , aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) ≤ 5x ULN . No hypercalcemia : ionized calcium ≤1.5 mmol/L . Patients buffer range normal value +/ 5 % hematology +/ 10 % biochemistry acceptable . This apply Renal Function , include Creatinine . Women child bear potential ( WOCBP ) must negative serum ( urine ) pregnancy test within 14 day trial registration . Patients childbearing / reproductive potential use adequate birth control measure , define investigator , study treatment period least 6 month last study treatment . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly . Female subject breast feed discontinue nursing prior first dose study treatment 6 month last study treatment . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . Before patient registration , write informed consent must give accord International Conference Harmonization Good Clinical Practice ( ICH/GCP ) , national/local regulation . Evidence extrahepatic metastasis ( CRC ) . Previous chemotherapy metastatic disease surgical treatment ( e.g . surgical resection radiofrequency ablation ) liver metastasis . Previous radiotherapy embolization treatment liver allow . Major surgical procedure , open biopsy , significant traumatic injury liver within 4 week prior registration . Other malignancy 3 year prior study entry exception surgically cure carcinoma situ cervix , situ breast cancer , incidental finding stage T1a T1b prostate cancer , basal/squamous cell carcinoma skin . Prior ( less 12 month prior start treatment ) plan concurrent use antiangiogenic drug bevacizumab backbone chemotherapy Prior ( less 12 month prior start treatment ) plan concurrent use antiEpidermal Growth Factor Receptor ( EGFR ) monoclonal Antibody ( mAb ) panitumumab cetuximab backbone chemotherapy Regular use aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) . Ongoing bleed diathesis ( e.g . hemoptysis ≥ 1/2 teaspoon 2.5 mL ) , coagulopathy , need administration fulldose anticoagulant ( ) . Known history myocardial infarction and/or stroke within 6 month prior registration /or New York Heart Association ( NYHA ) class III IV congestive heart failure . Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) , history hypertensive crisis , hypertensive encephalopathy . History evidence upon physical examination Central Nervous System ( CNS ) metastasis . Bowel obstruction . Known allergy excipient standard chemotherapy agent Known intolerance atropine loperamide . Gilbert syndrome . Treatment Cytochrome P450 3A4 ( CYP3A4 ) inducer , unless discontinue &gt; 7 day prior step 2 registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>DWI-MRI</keyword>
	<keyword>resectable liver metastasis</keyword>
</DOC>